Cytocore, Inc.

Corporate Snapshot

CytoCore, Inc. ("CytoCore" or "the Company") is a biomolecular diagnostics and medical device company engaged in the design, development, and commercialization of cost-effective systems for the early detection of cancer and cancer-related diseases, and for the local delivery of drugs to sites affected by disease. CytoCore is developing the InPath™ System—a multi-component, comprehensive method to detect cervical precancer (dysplasia) and cancer lesions and to treat dysplasia in women worldwide. The InPath™ System is designed to be more accurate, rapid, cost-effective, and easier to use than traditional Papanicolaou ("Pap") or human papillomavirus (HPV) testing, and is capable of providing patients with point-of-service (POS) test results. The InPath™ System consists of a family of four novel, proprietary products designed to be used separately or as a unified solution: the e2 Collector™ (a U.S. Food and Drug Administration [FDA]-approved cell collection device); the Cocktail-CVX™ and Cocktail-GCI (assays used to identify the presence of abnormal cells in the cervical cytology sample through proteomics, a fluorescent staining process); the Automated Imaging Proteomic System (AIPS) platform (a microscope workstation capable of high-throughput sample evaluation); and a Drug Delivery System ([DDS] to provide therapeutic treatment for cervical lesions at the point-of-care). CytoCore’s assays employ the P2X7 biomarker, which can detect cancerous uterine epithelial cells, as well as precancerous tissue and early neoplastic lesions. The P2X7 biomarker has also recently shown to accurately detect bladder cancer, suggesting its potential for use in the early detection of cancer in other epithelial tissues. CytoCore is further developing an Endometrial Cancer Scan based on the P2X7 marker, which has entered a Fast Track Phase I trial and has been shown in preliminary studies to represent more than 95% of uterine cancers.